Clinical Trial Detail

NCT ID NCT04432857
Title AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Adlai Nortye Biopharma Co., Ltd.
Indications

triple-receptor negative breast cancer

lung squamous cell carcinoma

bladder urothelial carcinoma

colorectal cancer

cervical cancer

lung non-squamous non-small cell carcinoma

Therapies

E7046 + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.